Bulk RNAseq of primary CD34+ HSPCs in Myeloproliferative neoplasms patients receiving tamoxifen

ABSTRACT: TAMARIN study is a Phase II, multicenter, single arm A’herns design clinical trial assessing tamoxifen’s safety and activity in reducing molecular markers of disease burden in MPN.The primary outcome (≥50% allele burden reduction at 24 weeks) was met by 3/37 patients; 5/37 additional patients showed ≥25% reductions. CD34+ HSPCs were collected from responders and non-respondersin the baseline line and 24W after tamoxifen treatment. RNAseq was performed to investigate the molecular signature about tamoxifen sensitivity and pharmacological mechanism of tamoxifen in MPN patients.

ORGANISM(S): Homo sapiens

PROVIDER: GSE172022 | GEO | 2023/10/02

REPOSITORIES: GEO